Cure8 research brief
The study compares two oral steroid therapies used to induce remission in outpatient ulcerative colitis and reports similar short-term efficacy but different safety profiles — information that can inform treatment discussions between patients and clinicians.
Adults with ulcerative colitis considering outpatient induction therapy, clinicians who prescribe steroids for UC, and caregivers involved in treatment decisions.
This study looked at consecutive outpatients started on either oral prednisolone or BUD-MMX and measured clinical remission at 8 weeks using the partial Mayo score. Overall remission was 65% with prednisolone and 55% with BUD-MMX; clinical response rates were 75% and 62.5%, respectively.
Adverse events were reported more often with prednisolone (23.3% vs 2.4%). The choice of therapy in practice appeared tied to baseline disease severity; fewer patients with low baseline partial Mayo scores received prednisolone.
The findings suggest BUD-MMX may be a reasonable initial option for some patients, particularly where clinicians prefer a steroid with a different safety profile. Because this is a retrospective cohort from two tertiary centers, treatment allocation was not randomized and may reflect physician selection based on disease severity.
Retrospective, non-randomized design and treatment selection according to baseline disease activity limit causal conclusions. The content is grounded in the article abstract; full-text review may provide additional details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...
The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
